What is Engine Biosciences?
Headquartered in Singapore and established in 2014, Engine Biosciences operates as a specialized biotechnology firm that integrates machine learning with genomic data to streamline drug discovery. By decoding the complex interactions within biological systems, the company aims to identify novel therapeutic targets more efficiently than traditional laboratory methods. Its market position is defined by its ability to bridge the gap between computational intelligence and wet-lab validation, a dual-capability approach that is increasingly vital in the modern pharmaceutical landscape.
How much funding has Engine Biosciences raised?
Engine Biosciences has raised a total of $88M across 3 funding rounds:
Angel/Seed
$10M
Other Financing Round
$18M
Series A
$60M
Angel/Seed (2018): $10M, investors not publicly disclosed
Other Financing Round (2023): $18M led by Polaris Partners and EDBI
Series A (2023): $60M supported by Dimensions Capital, Goodman Capital, Baidu Ventures, Nest.Bio, DHVC, Polaris Partners, WuXi AppTec, WI Harper Group, Invus, Vectr Ventures, and EDBI
Key Investors in Engine Biosciences
Baidu Ventures
An independent venture fund established by Baidu, focusing on supporting entrepreneurs who are spearheading the new age of artificial intelligence and computational genetics.
6 Dimensions Capital
A specialized investment firm focused on innovative life science companies, operating with a strong presence in both China and the United States.
EDBI
A global investor based in Singapore that focuses on high-growth technology sectors, aiming to catalyze growth and transform industries through strategic capital.
What's next for Engine Biosciences?
With the successful closure of its Series A round, Engine Biosciences is well-positioned to scale its operational capacity and expand its research initiatives. The influx of capital will likely be directed toward enhancing its proprietary AI engine, expanding its internal drug discovery programs, and fostering strategic partnerships with global pharmaceutical entities. As the company moves into this next phase of growth, the focus will shift toward clinical validation and the commercialization of its most promising therapeutic candidates, further cementing its role as a leader in the AI-enabled biotech sector.
See full Engine Biosciences company page
